A case report on αIN antibody-mediated paraneoplastic cerebellar ataxia.

Clin Neurol NeurosurgFeb 28, 2026 (epub)

Dan Wang, Min Li, Bin Liu et al.

✦ AI-curated · Sources linked

Case in brief

A 68-year-old woman developed subacute blurred vision, leg weakness, and dysarthria after SARS-CoV-2 infection. Examination showed nystagmus, dysarthria, and limb ataxia. Arterial spin-labeling MRI demonstrated hypoperfusion in both cerebellar hemispheres, and α-internexin antibodies were detected in serum and cerebrospinal fluid. Bronchoscopy suggested small-cell lung cancer, supporting a diagnosis of αIN antibody-associated paraneoplastic cerebellar ataxia. Intravenous immunoglobulin was followed by partial symptom improvement.

What made this case unusual

The diagnostic picture combined cerebellar hypoperfusion on arterial spin-labeling MRI with αIN antibodies in both serum and CSF, alongside bronchoscopy findings suggestive of small-cell lung cancer.

Diagnostic / clinical pearl

In a patient with cerebellar ataxia and suspected malignancy, αIN antibody testing in serum and CSF may help identify a paraneoplastic neurological syndrome.

Source

Published in Clin Neurol Neurosurg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.